2022 World Conference on Lung Cancer (ePosters)-EP16.02-018. Liquid Biopsies First to Make Treatment Decisions in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC)

EP16.02-018. Liquid Biopsies First to Make Treatment Decisions in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the use of liquid biopsies (LB) in treatment decision making for patients with metastatic non-small cell lung cancer (mNSCLC). The study compared LB results to tissue biopsies (TB) in 170 patients diagnosed with mNSCLC. LB was found to be a good complement to TB in identifying actionable genetic alterations (AGA) in newly diagnosed patients with mNSCLC. LB was also shown to be a faster and more accurate method, with treating oncologists basing their treatment decisions on LB results three times more often than TB. LB was able to report next generation sequencing (NGS) results significantly faster, overcoming the logistical barriers of finding and shipping tissue samples for sequencing.<br /><br />The study found that LB could be incorporated as a standard of care to guide first-line therapy decisions in most patients with mNSCLC due to its accuracy and shorter turnaround time (TAT). LB had a median TAT of 9 days, compared to 28 days for TB. The majority of treatment decisions, 74%, were based on LB results, while only 25% were based on TB results.<br /><br />The study also compared the accuracy of LB and TB in detecting specific genetic aberrations. LB had higher sensitivity and specificity compared to TB for detecting EGFR, BRAF, ALK, MET, NTRK, and ROS1 aberrations. LB had a concordance rate of 94.8% to 100% for these genetic aberrations, indicating a high level of agreement between LB and TB.<br /><br />Overall, the study demonstrated that LB can be used as the first modality for treatment decision making in patients with mNSCLC. LB has advantages over TB in terms of speed, accuracy, and overcoming logistical barriers. The study suggests that LB can be incorporated as a standard of care in guiding therapy decisions for patients with mNSCLC.

Asset Subtitle

Luis Raez

Meta Tag

Speaker Luis Raez

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

retrospective study

liquid biopsies

treatment decision making

metastatic non-small cell lung cancer

actionable genetic alterations

tissue biopsies

next generation sequencing

turnaround time

genetic aberrations

standard of care